Clinical Trial Update: Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane (Aromasin) in Postmenopausal Women [Phase 2]

View source ↗

Summary

Open-label, multicenter Phase 2 randomized controlled study evaluating intramuscular or oral exemestane (Aromasin) in postmenopausal women with breast cancer. T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Aromasin (exemestane)

Snippet

Sponsor: Pfizer | Conditions: Breast Neoplasms | Phase 2 | Status: TERMINATED